Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Revue Neurologique
- Vol. 174 (4) , 255-264
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis opticaNeurology, 2013
- Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis OpticaJournal of Immunology Research, 2013
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- Pregnancy outcomes after maternal exposure to rituximabBlood, 2011
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trialAnnals of Neurology, 2009
- Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximabMultiple Sclerosis Journal, 2009
- Antibody to aquaporin-4 in the long-term course of neuromyelitis opticaBrain, 2008
- Consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006